I

    Instil Bio Inc. (TIL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.61
    +0.03 (+0.40%)

    Market Cap: $51.41M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    32%(7/22)
    Avg Surprise
    -4.53%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.17
    Range$-0.17 - $-0.17
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.33-94.1%
    60d ago$-0.33-94.1%
    30d ago$-0.17+0.0%
    7d ago$-0.17+0.0%
    Current$-0.17
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.06
    Range$-0.06 - $-0.06
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.06---
    Sep 26EST
    		-$-0.17---
    Jun 26
    		$-0.63$-0.35-80.00%Miss+78.1%
    Mar 26
    		$-0.62$-0.59-5.08%Miss+85.6%
    Dec 25
    		$-0.97N/A+74.34%Beat+10.2%
    Sep 25
    		$-2.01$-2.35+14.47%Beat+21.2%
    Jun 25
    		$-2.88$-2.44-18.03%Miss-83.4%
    Mar 25
    		$-4.32$-2.59-66.80%Miss-15.5%
    Dec 24
    		$-1.08N/A+70.41%Beat+14.3%
    Sep 24
    		$-2.55$-3.08+17.21%Beat+20.3%
    Jun 24
    		$-1.57$-3.04+48.36%Beat+28.6%
    Mar 24
    		$-3.74$-2.23-67.71%Miss+25.2%
    Dec 23
    		$-1.26N/A+62.94%Beat-425.0%
    Sep 23
    		$-3.20$-3.00-6.67%Miss+62.8%
    Jun 23
    		$-2.20$-2.00-10.00%Miss+76.1%
    Mar 23
    		$-5.00$-3.20-56.25%Miss+40.5%
    Dec 22
    		$-0.24$-0.41+41.46%Beat+44.2%
    Sep 22
    		$-8.60$-8.20-4.88%Miss-30.3%
    Jun 22
    		$-9.20$-8.27-11.25%Miss-70.4%
    Mar 22
    		$-8.40$-6.50-29.23%Miss+36.4%
    Dec 21
    		$-0.43$-0.36-19.44%Miss-186.7%
    Sep 21
    		$-6.60$-6.13-7.67%Miss-
    Jun 21
    		$-5.40$-4.00-35.00%Miss-
    Mar 21
    		$-13.20$-11.90-10.92%Miss-
    Dec 20
    		$-0.15$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.80EV/EBITDA0.62x
    Price/FCF-2.19xFCF Yield-45.75%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-25.30%ROIC-15.39%
    Financial Health
    Debt/Equity0.79xInterest Coverage-5.97x
    Current Ratio21.67xQuick Ratio21.67x
    Trading Statistics
    Beta1.91Avg Volume7.68K
    52-Week High$33.8352-Week Low$5.67

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.60
    SMA 20$7.48
    SMA 50$7.47
    SMA 200$8.58
    EMA 10$7.61
    EMA 20$7.53
    EMA 50$7.56
    EMA 200$9.87

    MACD

    Line: 0.07Signal: 0.04Hist: 0.04

    ADX

    ADX: 20.4+DI: 17.1-DI: 12.0

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down16.0
    PSAR$7.88

    Bollinger Bands

    Upper Band$7.86
    Lower Band$7.10
    %B Position1016%(Upper)
    Band Width0.67

    RSI (14-Day)

    Neutral
    53.5

    Momentum Oscillators

    Stoch %K67.2
    Stoch %D75.8
    Williams %R-44.5
    ROC (10d)3.4%
    Momentum0.25
    CCI (20d)60.1
    MFI (14d)49.1

    Volatility Measures

    ATR (14d)$0.23(3.1%)
    StdDev (20d)0.19
    Hist Vol27.7%(Moderate)

    Volume Flow

    VWAP$7.61
    OBV-705.5K
    AD Line-3.7M
    CMF (20d)0.048

    Volume Metrics

    Avg Vol (20d)7.6K
    Vol Ratio0.3x(Low)
    VWMA (20d)$7.50

    Pivot Points

    R3$8.17
    R2$8.00
    R1$7.79
    Pivot Point$7.62
    S1$7.41
    S2$7.24
    S3$7.03

    Advanced Oscillators

    TSI11.62
    Ultimate Osc51.3
    KST24.40

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$3.99M$0$0$0$7.67M$0
    Cost of Revenue$0$0$12,000$0$0$0$741,000$0$0$0$1.04M$0
    Gross Profit$0$0$-12,000$0$0$0$-741,000$0$0$0$-1,036,000$0
    Operating Expenses$5.58M$5.39M$9.56M$15.02M$23.44M$30.56M$11.82M$23.63M$14.13M$23.95M$13.02M$66.72M
    R&D$270,000$669,000$3.50M$9.13M$16.74M$5.37M$1.10M$10.56M$2.92M$7.26M$1.98M$8.49M
    SG&A$5.13M$5.35M$6.06M$5.89M$6.16M$9.11M$10.37M$10.71M$10.71M$12.42M$10.87M$11.94M
    Operating Income$-5,581,000$-7,010,000$-9,557,000$-15,022,000$-23,440,000$-30,562,000$-11,820,000$-23,631,000$-14,135,000$-23,955,000$-13,020,000$-66,716,000
    Interest Income$2.87M$2.92M$2.99M$3.13M$3.29M$3.42M$4.13M$3.15M$1.92M$2.06M$2.19M$2.31M
    Interest Expense$1.58M$1.55M$1.57M$1.58M$1.58M$1.10M$3.00M$2.01M$2.00M$1.98M$1.98M$2.00M
    Income Before Tax$-4,289,000$-4,204,000$-8,191,000$-13,587,000$-21,394,000$-28,243,000$-11,895,000$-23,021,000$-14,917,000$-24,302,000$-12,925,000$-67,432,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-4,299,000$-4,204,000$-8,191,000$-13,587,000$-21,394,000$-28,200,000$-11,895,000$-23,021,000$-14,917,000$-24,302,000$-12,925,000$-67,432,000
    EBITDA$-5,253,000$-7,002,000$-9,600,000$-15,128,000$-23,031,000$-30,300,000$-12,275,000$-23,260,000$-13,862,000$-23,390,000$-12,104,000$-66,789,000
    EBIT$-5,581,000$-7,192,000$-9,612,000$-15,140,000$-23,098,000$-30,562,000$-13,016,000$-24,161,000$-14,837,000$-24,383,000$-13,140,000$-67,742,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TIL

    News

    Why (TIL) Price Action Is Critical for Tactical Trading

    This article analyzes Instil Bio Inc. (NYSE: TIL) using AI models to suggest trading strategies based on price action. It identifies neutral readings in shorter horizons, potentially signaling an easing of a long-term weak bias, and highlights compelling upside potential with no remaining resistance levels above the current price. The report outlines position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for tactical traders.

    Stock Traders Daily•8/14/26•
    Neutral

    Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    Instil Bio (Nasdaq: TIL) reported its second-quarter 2026 financial results, highlighting a cash position of approximately $69.9 million as of June 30, 2026, which is expected to fund operations beyond 2027. The biotechnology company is actively evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates. The report also detailed reduced operating expenses and a net loss per share of $0.63 for the quarter, significantly lower than the previous year.

    The Manila Times•8/14/26•
    Neutral

    Form 8K Instil Bio Inc For: 13 August By Investing.com

    This article from Investing.com is a simple announcement regarding Instil Bio Inc.'s Form 8K filing for August 13th. It provides no further details beyond the headline and the company's stock ticker (TIL). The core purpose is to inform readers about the availability of this specific SEC filing.

    Investing.com Nigeria•8/13/26•
    Neutral

    Instil Bio, Inc. 2026: Revenue ($4.35M), Net income ($4.3M), EPS ($0.63) — 10-Q Summary

    Instil Bio, Inc. reported its 2026 quarterly results, showing a significantly narrower net loss and reduced comprehensive loss compared to the previous year. This improvement is attributed to the company winding down development of its lead candidate, AXN-2510, and substantially cutting R&D activity and headcount. The company is now focusing on in-licensing or acquiring new therapeutic candidates and maintaining a lean R&D footprint, with current cash reserves supporting operations into future periods.

    TradingView•8/13/26•
    Somewhat-Bullish

    Instil Bio (TIL) slashes R&D spend and leans on Tarzana lease income in Q2 2026

    Instil Bio (TIL) significantly reduced operating expenses and narrowed its net loss in Q2 2026 due to the discontinuation of certain R&D programs and restructuring efforts. The company reported a net loss of $4.3 million for the quarter and $8.5 million for the first half of 2026, supported by $4.5 million in rental income from its Tarzana facility. While current liquidity of $69.9 million is expected to fund operations beyond 2027 with a planned loan extension, the company faces a substantial debt of $85.6 million secured by the Tarzana facility, highlighting ongoing dependence on external capital and future business development.

    Stock Titan•8/13/26•
    Somewhat-Bearish

    Frequently Asked Questions About TIL

    Does TIL pay dividends?
    Instil Bio Inc. (TIL) does not currently pay a regular dividend.
    What is TIL's market cap?
    Instil Bio Inc. (TIL) has a market capitalization of $51.41M with a current stock price of $7.61.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In